Prostamax (KEDP)
KEDP Tetrapeptide | Prostate Bioregulator
Community Research
Join others researching Prostamax — share findings, ask questions, and learn from real experiences
Prostamax is a Khavinson bioregulator tetrapeptide (KEDP) with primary repair effects on prostate tissue. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it alters chromatin structure in cells from elderly individuals, promoting deheterochromatinization and potentially reactivating genes repressed during aging. Research in rat models shows reduced prostate inflammation, decreased swelling, and decelerated pathological remodeling associated with prostatitis.
Prostamax works through epigenetic regulation by altering chromatin structure. It increases the frequency of sister chromatid exchanges and Ag-positive nucleolar organizer regions (NORs), while reducing large segments of pericentromeric heterochromatin. These changes promote chromatin decondensation and deheterochromatinization, potentially reactivating genes repressed during aging. The peptide influences heterochromatin arrangements in human lymphocytes and normalizes age-related changes in cellular function.
Molecular Data
KEDPLysine
Position 1
Glutamic Acid
Position 2
Aspartic Acid
Position 3
Proline
Position 4
Research Indications
Research shows reduced inflammation and swelling in prostatitis models.
Mitigates inflammation and immune cell infiltration in prostate tissue.
Decreases scarring and pathological remodeling in prostate.
Promotes deheterochromatinization in elderly cells.
Potentially reactivates genes repressed during aging process.
Normalizes age-related changes in lymphocyte function.
Dosing Protocols
Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Standard protocol | 10-20 mg | Daily for 10-20 days | Oral capsules |
| Maintenance | 10 mg | 2-3 cycles yearly | Oral capsules |
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Generally well-tolerated
- Minimal side effects reported
Stop Signs - Discontinue if:
- Allergic reactions
- Unusual urinary symptoms
Contraindications
- Prostate cancer (consult oncologist)
- Known hypersensitivity
- Pregnancy (not applicable)
Quality Checklist
Good Signs
- White powder or capsules
- Clear solution if reconstituted
- Proper packaging and labeling
Warning Signs
- Unknown source or purity
Bad Signs
- Discoloration
- Unusual odor
- Damaged packaging
Frequently Asked Questions
Is Prostamax safe to take if I have a family history of prostate cancer?
No. The safety flags include 'carcinogenic-risk,' and the contraindications explicitly state you should consult an oncologist if you have prostate cancer. While Prostamax targets benign prostate conditions, the carcinogenic-risk flag suggests unknown interactions with cancer development. Family history warrants professional medical consultation before use.
How does Prostamax reduce prostate swelling without hormone manipulation?
Prostamax works through epigenetic chromatin remodeling—it alters the physical structure of chromatin by increasing sister chromatid exchanges and decreasing heterochromatin. This promotes 'deheterochromatinization,' reactivating genes silenced during aging. It doesn't block hormones; it resets gene expression patterns in prostate cells.
Can Prostamax help with benign prostatic hyperplasia (BPH)?
Yes. Animal studies show Prostamax reduces prostate inflammation, swelling, and scarring—the key pathologies in BPH. However, these are preclinical results in rats. Human clinical trials are absent. If you have BPH, discuss with your urologist about whether Prostamax might complement standard treatments like alpha-blockers.
Should I get a PSA test before starting Prostamax?
Yes. The file recommends PSA testing for men over 50 before use. This is essential to establish a baseline and rule out prostate cancer before starting. Repeat PSA testing during treatment is prudent, especially given the carcinogenic-risk flag in the pharmacology section.
References
- Experimental Studying of Drug Efficiency Prostamax in Therapy of Chronic Aseptic ProstatitisBulletin of Experimental Biology and Medicine (2013)
Prostamax reduced prostate swelling, inflammation, and scarring in rat prostatitis models.
- Effects of Short Peptides on Lymphocyte Chromatin in Senile SubjectsBulletin of Experimental Biology and Medicine (2004)
KEDP peptide alters chromatin structure, promoting deheterochromatinization in elderly cells.
- Deheterochromatinization of Chromatin in Old Age Induced by Oligopeptide Bioregulator (Lys-Glu-Asp-Pro)Georgian Medical News (2012)
Prostamax promotes chromatin decondensation and reactivates age-repressed genes.
- Khavinson Peptide BioregulatorsAdvances in Gerontology (2020)
Comprehensive review of bioregulator peptides and their epigenetic mechanisms.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.